Li, Wei
- University of Tennessee Health Science Center · Pharmacology (NIH department code)
- University of California-Irvine · Biochemistry (NIH department code)
- Baylor College of Medicine · Ophthalmology (NIH department code)
- Penn State College of Medicine · Pediatrics (NIH department code)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #399
- Rising Star
- Sustained Excellence
- Top 5% Funded
- R01 Holder
- Long-Funded
- Translational
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2006 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2023 award categories
- Pharmacology
- Biochemistry
- Ophthalmology
- Pediatrics
- Neurosciences
NIH Funding · FY2023
Linked Award Amount
$7.6M
Full award amounts, FY2023
Award Records
14
Records listing this PI
Award-Linked Rank
#399
By linked amount among FY2023 PIs
Earliest Year Loaded
2006
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Li, Wei as a PI. Multi-PI records show the full award amount for context.
- 1ZIAEY000488-15ZIAContact PIAdaptive changes of the ground squirrel retina during hibernation$1.6Maward amount
- $1.2Maward amount
- 1R01CA276152-01R01Contact PITargeting brain and bone metastases in metastatic breast cancer for improved patient survivalUniversity of Tennessee Health Science Center · Pharmacology (NIH department code)$614.9Kaward amount
- 5R01CA228140-05R01Contact PITransfer: DNA Methylation Canyons in Human Cancers: Methods, Target Genes and Functional ConsequencesUniversity of California-Irvine · Biochemistry (NIH department code)$550.2Kaward amount
- 5R01CA240447-04R01Contact PIDual inhibition of MDM2 and XIAP as a therapeutic strategy in cancer$530.7Kaward amount
- 5R01HG010753-05R01Contact PIModeling Functional Elements using CRISPR Screening$446.3Kaward amount
- 1R21EY035421-01R21Contact PIDeveloping a novel disease-targeted anti-angiogenic therapy for CNVBaylor College of Medicine · Ophthalmology (NIH department code)$440Kaward amount
- 1R41NS135658-01R41Contact PIDeveloping a selective TRPC3 ion channel inhibitor for epilepsy treatment$429.9Kaward amount
- 5R01NS119547-03R01Contact PIThe role and mechanism of necrosis in glioblastomaPenn State College of Medicine · Pediatrics (NIH department code)$393.5Kaward amount
- 5R01CA148706-13R01Contact PITargeting the colchicine binding site in tubulin for cancer therapyUniversity of Tennessee Health Science Center · Pharmacology (NIH department code)$389.8Kaward amount
+4 more grants not shown.
Award organizations
Organizations that administered FY2023 awards listing Li, Wei as a PI.
National Eye Institute
$2.8M
2 grants
University of Tennessee Health Science Center
TN
$1.5M
3 grants
University of California-Irvine
CA
$903.3K
2 grants
Children's Research Institute
DC
$715K
2 grants
Baylor College of Medicine
TX
$440K
2 grants
Seak Therapeutics, LLC
$429.9K
1 grant
Penn State College of Medicine
PA
$393.5K
1 grant
University of Alabama at Birmingham
AL
$364.9K
1 grant
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2006First NIH AwardNational Eye Institute
- 2006$500K Cumulative Funding
- 2006Entered Top 50% NationallyRanked #8902
- 2007$1M Cumulative Funding
- 2007Multi-Institutional ResearchAwards at 8 institutions
- 2008$2M Cumulative Funding
- 2008Entered Top 25% NationallyRanked #3321
- 2009$5M Cumulative Funding
- 2011$10M Cumulative Funding
- 2011Entered Top 10% NationallyRanked #1953
- 2012R01 Grant Holder
- 2016$25M Cumulative Funding
- 2016Entered Top 5% NationallyRanked #767
- 2021$50M Cumulative Funding